PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 25 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A herbal preparation containing E. parviflorum (among other ingredients) showed a significant reduction in the International Prostate Specific Score (IPSS) total median score over 3 months [PMID:23642948]
Oral administration of E. parviflorum extract for 60 days resulted in a 40% decrease in prostate volume and a 20-30% decrease in serum testosterone concentration [PMID:40033986]
Extracts inhibited LNCaP cell proliferation (IC50 ~35 µg/ml), reduced PSA secretion, and inhibited arginase activity in vitro [PMID:23436427]
Methanolic extracts demonstrated cytotoxic potential in human malignant melanoma cell lines (A375 and COLO-679) in vitro [PMID:37111814]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 38201729 (2023) — Influence of Epilobium parviflorum Herbal Extract on Physicochemical Properties of Thermoplastic Starch Films. · Polymers
- 2.PMID: 38518615 (2024) — Development of UV-Vis spectroscopy-based analysis method for determination of tin(IV) in epilobium parviflorum (hoary willowherb) tea using deep eutectic solvent based preconcentration. · Food chemistry
- 3.PMID: 40362886 (2025) — The Involvement of Epilobium parviflorum in Different Human Diseases, with Particular Attention to Its Antioxidant and Anti-Inflammatory Properties and Benefits to Vascular Health. · Nutrients
- 4.PMID: 32544580 (2020) — Synthesis, characterization, biological activities and molecular docking of Epilobium parviflorum aqueous extract loaded chitosan nanoparticles. · International journal of biological macromolecules
- 5.PMID: 37111814